Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Oleclumab in PDAC, NSCLC, and SCCHN
NCT04262388Phase 2Withdrawn
- Sponsor
- University Health Network
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of oleclumab in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (HNSCC) (2 cohorts), sponsored by University Health Network. Primary endpoints: Association between cfMeDIP and Toxicity at 2 years, Objective Response Rate at 2 years and 2 more. Planned start Jan 2021; status: withdrawn.
02
Drugs
oleclumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04262388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262388.